Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 13/20 | 0.48 |
| ▸ | RARG | P13631 | 12/20 | 0.48 |
| ▸ | RARA | P10276 | 10/20 | 0.48 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CRABP2 | P29373 | 1/20 | 0.41 |
| ▸ | RXRA | P19793 | 9/20 | 0.41 |
| ▸ | RXRB | P28702 | 2/20 | 0.40 |
| ▸ | RXRG | P48443 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6578028 | 0.89 | RARB (0.41) | RARBRARGRARACYP26A1CYP3A4 | |
| SCHEMBL6578025 | 0.85 | RARB (0.65) | RARBRARGRARACYP26A1CYP3A4 | |
| SCHEMBL6578640 | 0.77 | RARB (0.49) | RARBRARGRARACYP26A1CYP3A4 | |
| SCHEMBL6575696 | 0.77 | RARB (0.46) | RARBRARGRARACYP26A1CYP3A4 | |
| SCHEMBL6574370 | 0.77 | RARB (0.67) | RARBRARGRARACYP26A1CYP3A4 | |
| SCHEMBL22426598 | 0.77 | RARB (0.67) | RARBRARGRARACYP26A1CYP3A4 | |
| SCHEMBL6575676 | 0.76 | RARB (0.39) | RARBRARGRARACYP26A1CYP3A4 | |
| SCHEMBL6574397 | 0.76 | RARA (0.37) | RARBRARGRARA | |
| SCHEMBL6578008 | 0.74 | RARB (0.51) | RARBRARGRARACYP26A1CYP3A4 | |
| SCHEMBL24410708 | 0.72 | RXRA (0.58) | RARBRARGRARACYP26A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0937045-B1 | N-ARYL SUBSTITUTED TETRAHYDROQUINOLINES LIGANDS FOR RETINOID RECEPTORS HAVING AGONIST, ANTAGONIST OR INVERSE AGONIST TYPE ACTIVITY | ALLERGAN INC (US) | 2004-04-28 | — | — | EP | disclosed |
| EP-0937045-A1 | N-ARYL SUBSTITUTED TETRAHYDROQUINOLINES LIGANDS FOR RETINOID RECEPTORS HAVING AGONIST, ANTAGONIST OR INVERSE AGONIST TYPE ACTIVITY | Allergan Sales, Inc. (US) | 1999-08-25 | — | — | EP | disclosed |
| WO-1998019999-A1 | N-ARYL SUBSTITUTED TETRAHYDROQUINOLINES LIGANDS FOR RETINOID RECEPTORS HAVING AGONIST, ANTAGONIST OR INVERSE AGONIST TYPE ACTIVITY | ALLERGAN SALES, INC. (US) | 1998-05-14 | — | — | WO | disclosed |
| US-5739338-A | SKIN DISORDERS, ANTIINFLAMMATORY AGENTS, ANTITUMOR AGENTS, VISION DEFECTS, VIRICIDES, IMMUNOSUPPRESSANTS | ALLERGAN (US) | 1998-04-14 | — | — | US | disclosed |